The extent of PD-L1 expression is notably higher in this subgroup than in other PTCLs, and is also associated with pSTAT3 expression, which makes PD-L1 a potential therapeutic target for ALK+ ALCL [82]. This evidence concerns the gene ALK and anaplastic large cell lymphoma.